ENDPOINTS NEWS21m
Ab­b­Vie part­ners with Sim­cere Phar­ma unit to de­vel­op myelo­ma drug
AbbVie partners with Simcere Zaiming in up to $1.1B deal to develop SIM0500 for multiple myeloma; drug currently in Phase 1 ...
ENDPOINTS NEWS49m
Im­muno­vant’s $450M pri­vate place­ment; Bio­mea be­comes an obe­si­ty biotech
Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.